EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?

Klaus Schmierer iD, Frederick Chen, David Paling iD

European Journal of Neurology · 2026-07 · 33 (7)

DOI: 10.1111/ene.70698 ↗

At a glance

Journal article in European Journal of Neurology, published online on 2026-07-06. Written by Klaus Schmierer and 2 co-authors. Institution: The Blizard Institute, Queen Mary University of London, Faculty of Medicine & Dentistry, London, UK. Major MEDLINE topics: Blood Transfusion, Cladribine, Graft vs Host Disease, Immunosuppressive Agents. 15 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Irradiation of cellular blood components prevents transfusion‐associated graft‐versus‐host disease (TA‐GVHD). UK and Spanish guidance recommend lifelong irradiation for all patients treated with purine analogues, including cladribine, irrespective of indication or dose.

Objective

To assess whether this approach is justified for people with multiple sclerosis (pwMS) receiving cladribine.

Methods

Narrative synthesis of immunological data, hemovigilance evidence, and national European transfusion guidelines.

Results

Cladribine used in pwMS induces transient lymphopenia with modest, reversible T‐cell effects and preserved vaccine responsiveness. Since introduction of universal pre‐storage leucocyte depletion, hemovigilance data show no reported cases of TA‐GVHD in this setting. European guidance is heterogeneous, ranging from indefinite to time‐limited or unspecified durations.

Conclusion

Current evidence does not clearly support the need for lifelong irradiation after cladribine treatment in pwMS. Time‐limited or individualized approaches merit consideration.

Subjects

MeSH terms (MEDLINE)

Blood TransfusionCladribineGraft vs Host DiseaseImmunosuppressive AgentsMultiple SclerosisTransfusion ReactionHumans

Author keywords

cladribinedisease modifying therapiesmultiple sclerosistransfusion‐associated graft‐versus‐host disease

Substances

CladribineImmunosuppressive Agents

Authors and institutions

  • The Blizard Institute, Queen Mary University of London, Faculty of Medicine & Dentistry, London, UK.
  • Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
  • Clinical Haematology, The Royal London Hospital, Barts Health NHS Trust, London, UK.
  • Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK.

ORCID profiles: Klaus Schmierer, David Paling

Cite

APA

Schmierer, K., Chen, F., & Paling, D. (2026). Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?. European Journal of Neurology, 33(7). https://doi.org/10.1111/ene.70698

Vancouver

Schmierer K, Chen F, Paling D. Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?. European Journal of Neurology. 2026;33(7). doi:10.1111/ene.70698

BibTeX
@article{Schmierer2026,
  author = {Schmierer, Klaus and Chen, Frederick and Paling, David},
  title = {Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1111/ene.70698}
}
Start for free →